Articles tagged with Lung Cancer
Researchers at MD Anderson Cancer Center found that combination immunotherapy with durvalumab and novel agents outperforms durvalumab alone in early-stage non-small-cell lung cancer. The study showed higher major pathological response rates for combination therapy, with some regimens inducing up to 31.3% of MPR.
Researchers at the University of Liverpool are developing a novel immunotherapeutic strategy to treat non-small cell lung cancer. They will create personalized 'doggybone DNA' vaccines using rapid replication of genetic medicine.
A secondary analysis of NRG Oncology-RTOG 0617 found IMRT reduced CTCAE grade ≥ 3 pneumonitis by 2-fold compared to 3D-CRT. The study suggests IMRT should be the radiation technique of choice for patients with locally advanced NSCLC.
CityU and AFCR have signed a MoU to promote cutting-edge cancer-related innovative inventions and commercialization. The partnership aims to foster the development of biomedicine and related innovation, with world-leading scholars from Harvard Medical School attending the inaugural 'Innovation Series in Biomedicine' forum.
Researchers from Shinshu University identified citrullination as a key mechanism in lung cancer metastasis. A novel CitFbg peptide was developed to block metastatic cell homing and reduce the risk of cancer spread.
Research published in BMJ Oncology reveals a global increase of 79% in new cancer cases among those under 50 between 1990 and 2019. Breast cancer accounted for the highest number of early onset cases, while cancers of the windpipe and prostate rose the fastest.
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.
Researchers discovered that specific enzymes on immune cells can predict patient survival and response to immunotherapies. High levels of CD39 on cytotoxic T cells located within tumors are associated with increased survival and better response to treatment.
Cancer patients face reduced co-determination and insufficient information about treatment, while doctors feel pressured to give harmful treatments. Patients struggle to understand options and communicate with healthcare professionals.
A new study finds that integrating longitudinal tobacco cessation care into lung cancer screening improves quit rates and enhances the benefits of screenings. Researchers recommend incorporating behavioral treatment and medication into the screening process to help smokers quit.
A statistician at Virginia Commonwealth University has been awarded a $1.7 million grant to investigate the long-term effects of neighborhood exposures and racial segregation on cancer risk. The researcher aims to better understand how geographic and socioeconomic factors contribute to disparities in cancer incidence and mortality.
Researchers have identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer, associated with higher ki67 expression and aggressive clinical characteristics. MEK inhibitor trametinib may be effective in blocking the MEK-ERK signaling driven by this fusion.
A new study estimates that cancer screenings have saved the US at least $6.5 trillion and led to 12 million more years of life, with significant economic impact from breast, colon, cervical, and lung cancer screenings.
A large long-term study found that good cardiorespiratory fitness in young men is associated with a significantly lower risk of developing nine specific cancers, including a 40% reduced risk of liver cancer. Higher fitness was also linked to lower risks of rectal, pancreatic, and bowel cancers.
A biomolecule has been engineered to selectively target and remove mucins from cancer cells, reducing tumor growth and increasing survival in lab-grown human cancer cells and mouse studies. This discovery could play a significant role in future therapies for cancer, as mucins are associated with many diseases.
A new study from the University of East Anglia found that most vapers believe a 'Swap-to-Stop' scheme providing free e-cigarettes would have helped them quit smoking. However, some respondents prefer to purchase e-cigarettes commercially due to personal preference for specific products.
A meta-analysis of multiple studies found no association between depression and anxiety and most types of cancer. However, the study found a link between depression and anxiety with a 6% higher risk of developing lung cancer and smoking-related cancers.
Researchers at Dana-Farber Cancer Institute and Yale Cancer Center uncover epigenetic mechanism driving resistance to osimertinib in EGFR-mutant lung cancer. Blocking SWI/SNF chromatin remodeling complexes reverses resistance, suggesting new therapeutic strategy
The GEMINI blood test uses machine learning to identify cancer-causing mutations in single molecules of cell-free DNA. The test detected over 90% of lung cancers, including stage I and II cases, in a proof-of-concept study published in Nature Genetics.
A study published in Cell Death & Disease has characterized the cellular composition and spatial architecture of tumor microenvironment in human multiple primary lung cancers. The researchers identified a previously undescribed sub-population of epithelial cells, CLDN2+ alveolar type II (AT2), specifically enriched in MPLCs.
Researchers found that individuals exposed to wildfires within a year of lung cancer surgery had significantly lower overall survival rates compared to those not exposed. The closer the exposure occurred to the surgery, the worse the survival rate, with patients exposed 3-6 months after surgery facing a 48% decrease in survival chances.
A new study published in Radiology found that AI can use data from low-dose CT scans of the lungs to improve risk prediction for death from various causes. The study used data from over 20,000 individuals and found that body composition measurements derived from lung screening LDCT were strong predictors of mortality.
Using plasma circulating tumor DNA testing can expedite biomarker testing and time to treatment for patients with suspected advanced lung cancer. The study suggests that this approach may improve patient outcomes.
The July issue of CHEST journal features 49 articles on clinically relevant topics, including disability rights and life-sustaining treatment. The journal offers complementary web resources, such as visual abstracts, to expand the reach of its research.
A new study reveals that the cellular chaperone protein GRP78 migrates to the nucleus under stress and alters gene activities, allowing cancer cells to become more mobile and invasive. This discovery offers potential new approaches for cancer treatment, including down-regulating GRP78 activity or preventing it from binding to ID2.
A global study shows atezolizumab significantly improved overall survival and resulted in a clinically meaningful long-term survival benefit for advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy. The treatment also showed stabilised or improved health-related qualit...
A blood-based four-protein panel and personalized risk model can predict an individual's risk of dying from lung cancer, improving sensitivity and specificity compared to current guidelines. The test has the potential to save lives by determining the need for lung cancer screening on a personalized basis.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
A study published in Radiology found that AI algorithms with high diagnostic accuracy improved radiologists' detection of lung cancers on chest X-rays. High-accuracy AI led to more frequent changes in reader determinations, suggesting increased human trust in AI.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Researchers developed a risk calculator using persistent homology scores from CT scans, which is the strongest predictor of overall survival among standard clinical measures. The calculator has the potential to guide clinicians in choosing treatment options and transform the way outcomes are predicted.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
The study found a decreasing trend in the global TBL cancer burden from 1990 to 2019, but regional variations persisted. The burden was highest in upper-middle-income countries and lowest in high-income countries.
A new study from the Van Andel Research Institute reveals that loss of two key 'protector' proteins, TET and RYBP, transforms healthy lung cells into cancerous ones through epigenetic changes. The research found that deficiency of these proteins leads to widespread aberrant methylation and malignant transformation.
The study found that lung cancer screening rates among eligible adults in Maine, Michigan, New Jersey, and Rhode Island increased in 2021 compared to 2019. Consistent with prior studies, the likelihood of lung cancer screening was higher among individuals with a primary health professional
Researchers found adagrasib effective in suppressing cancer growth in both lungs and brain metastases, with a 90% intracranial disease control rate and 42% objective response rate. The median intracranial progression-free survival was 5.4 months, while the median overall survival reached 11.4 months.
A recent study reveals lower lung cancer screening rates among Black veterans, underscoring the need for further research into barriers to screening and evidence-based interventions. The findings suggest that demographics alone do not fully explain these disparities.
Researchers found a link between short telomeres in ATII cells and lung fibrosis in post-COVID-19 patients. The study revealed loss of ATII cellularity and shorter telomeres concomitant with increased fibrotic lung parenchyma remodeling.
The June issue of CHEST features 49 articles on clinically relevant topics, including asthma, COPD, and critical care. The journal offers web and multimedia resources to expand the reach of its research.
A new study published in JNCCN found that taking alectinib, a medication for advanced lung cancer, with a full breakfast or lunch resulted in higher drug concentrations than with a low-fat breakfast. This could impact treatment efficacy and survival rates for patients.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A Yale-led study found that osimertinib significantly improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer after surgery. The trial showed a 51% reduction in mortality risk, with 88% of patients surviving at least five years.
A new observational study published in BMJ Open found that long Covid can have a devastating effect on daily lives, with fatigue impacting social activities, work, and relationships. The study's findings suggest that long Covid can leave people with worse fatigue and quality of life than some cancers.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
The study, published in JAMA Oncology, found that the percentage of cancer survivors reporting functional limitations has more than doubled over the past 20 years. The adjusted prevalence of functional limitation was highest among pancreatic and lung cancer survivors, while melanoma survivors had the lowest rate.
A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
Researchers at UCLA Health highlight the impact of test results on lung cancer screening adherence and the potential unnecessary use of axillary ultrasound in breast cancer diagnostics. Meanwhile, a new AI system helps check endotracheal tube placement with high accuracy and user satisfaction.
A study by University of Technology Sydney found that plants can remove 97% of toxic compounds, including cancer-causing pollutants, from indoor air in just eight hours. This breakthrough discovery highlights the critical role played by indoor plants and green walls in improving air quality.
A new study published in the Journal of the American College of Surgeons predicts a significant increase in cancer cases due to COVID-19 screening delays, with lung, breast, and colorectal cancers most affected. The study found that missed diagnoses during the pandemic may lead to delays in treatment and upstaging of disease.
Researchers have studied targeting telomeres as a potential therapeutic strategy for non-small cell lung cancer. Telomere dysfunction and telomerase deficiency slowed tumor progression, increasing vulnerability to DNA damage and immune system response.
A study found that over half of English NSCLC patients living in low-socio-economic areas did not receive new anti-cancer therapies, despite having access to free treatment through the National Health Service. The researchers examined data from 90,785 patients diagnosed between 2012 and 2017.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers discovered that air pollution particles trigger autophagy, a cellular defense process, which has an upper threshold and may reduce its effectiveness against other threats. This finding provides new insights into the link between air pollution and lung disease.
The May issue of the CHEST journal features cutting-edge research on pulmonary, critical care, and sleep medicine. The journal also highlights awareness for cystic fibrosis, a once-fatal childhood condition now affecting adults.
Researchers at USC Norris Comprehensive Cancer Center have identified a biomarker, CX3CR1, that can predict which patients with non-small cell lung cancer will respond well to chemoimmunotherapy. Elevated levels of the biomarker in T-cells after six to nine weeks of treatment indicate long-term benefits from the combination therapy.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.